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Purpose: Stereotactic body radiation therapy (SBRT) for early-stage lung cancer can be achieved with several
methods: respiratory gating, body frame, or real-time target and motion tracking. Two target tracking methods are
currently available with the CyberKnifeW System: the first one, fiducial tracking, requires the use of radio-opaque
markers implanted near or inside the tumor, while the other, XsightW Lung Tracking System, (XLTS) is fiducial-free.
With XLTS, targeting is synchronized directly with target motion, which occurs due to respiration. While the former
method (fiducial tracking) is well documented, the clinical relevance of the latter (tracking without fiducials) has
never been well described to this date.
Patients and Methods: A study was performed at our department for each patient treated for lung cancer with
CyberKnife using XLTS. Selection criteria were: primary or recurring T1 or T2 stage non-small-cell lung cancer
(NSCLC) with 15–60 mm tumor size. Initial staging included CT-Scan and FDG-PET.
Results: Fifty-one patients not amenable to surgery were treated with XLTS. Median follow-up was 15 months
(range, 5–30 months). Median tumor size was 24 mm (range, 15–60 mm). Median total dose was 60 Gy (36–60 Gy)
in three fractions. Actuarial overall survival was 85.5% (95% CI = 74.5–96%) at 1 year and 79.4% (95% CI = 64–94.8%)
at 2 years. Actuarial local control rate was 92% (95% CI = 84–99%) at one1 year and 86% (95% CI = 75–97%) at
2 years.
Conclusion: Local control and overall survival rates were similar to previous reports that used fiducials for tumor
tracking. Toxicity was lower than most studies since tumor tracking did not require fiducial implantion. This
fiducial-free method for respiratory motion tracking is a valid option for the most fragile patients.
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Efficacy, ToxicityIntroduction
Stereotactic Body Radiation Therapy (SBRT) use is rap-
idly increasing among patients with lung cancer not
amenable to surgery. Several methods are currently
available suitable for the delivery of such high doses to
small volumes. The required precision can be attained
through several techniques, one of which involves* Correspondence: e-lartigau@o-lambret.fr
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reproduction in any medium, provided the ortracking the tumor’s movement in real time while the
patient breathes freely.
The CyberKnifeW system (Accuray Incorporated, Sun-
nyvale, California, USA) was first introduced in France
in 2006 through the financial support of the French Na-
tional Cancer Institute (INCa). It allows for stereotactic
body radiation therapy (SBRT) of lung cancer with real-
time target and motion tracking. Two target tracking
methods are currently available with the system: one of
them, Fiducial Tracking, requires the use of fiducial
markers implanted near or inside the tumor, while the
other, XsightW Lung Tracking System, (XLTS) is fiducial-
free. Both tumor tracking methods can be combinedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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which synchronizes the beam targeting during delivery
with the motion of the target due to respiration. While
the former (Fiducial Tracking with Synchrony) is well
documented, the efficacy and toxicity of the latter (XLTS
with Synchrony) has not been well described.
Transthoracic fiducial implantation is reportedly re-
sponsible for cases of pneumothorax in 13% of the
patients that undergo the procedure. [1] This rate may
actually be an underestimate as some studies have
reported rates of 23%, or even 38%, for transthoracic bi-
opsies [2-5]. Considering that the concerned population
of patients is often very fragile (elderly patients, those
with chronic lung disease or other malignancies), the
risk of pneumothorax should not be taken lightly.
Patients are sometimes excluded only because they
could not afford the risk of a pneumothorax. Fortu-
nately, other fiducial implantation techniques are avail-
able, such as electromagnetic navigation-guided
bronchoscopy or intravascular coil placement. However,
the use of radiomarkers has others risks beyond
pneumothorax, such as arrhythmias in the case of endo-
vascular coils. They must be inserted with high precision
for the tracking system to work, and sometimes they mi-
grate and cause a systematic error at each treatment ses-
sion. Finally, fiducial insertion may delay the treatment,
since it is better to perform the planning CT a few days
after the insertion.
With these difficulties in mind, a new system has been
developed to directly track the tumor instead fiducials.
XLTS is able to correlate intensity similarities in the
digitally reconstructed radiographs (DRRs) to the pos-
ition of the tumor when certain tumor criteria are met.Figure 1 Upper-left corner : treatment planning DRR; Lower-left corn
searching for the maximum similarity between DRR and live.This method may represent a shorter, completely unin-
vasive treatment for patients with lung cancer not amen-
able to surgery. In this study, we discussed the technical
aspects of this system, the precise patient selection cri-
teria required for its application, and the clinical out-
come in terms of both efficacy and toxicity for the 51
patients treated at our center between November 2008
and January 2011.
Patients and Methods
CyberKnife and Xsight Lung Tracking System
Pulmonary tumors larger than 15 mm and located in the
peripheral or apex regions are visible in the orthogonal
X-Ray images created by the CyberKnife System. Direct
tumor tracking is accomplished by matching the image
intensity pattern of the tumor region in the digitally
reconstructed radiographs (DRRs) to the corresponding
region in the treatment X-ray images (Figure 1). A cor-
relation model is then generated by fitting the internal
tumor positions at different phases of the breathing cycle
to the simultaneous external marker positions. During
treatment, the internal tumor position is estimated from
the external marker positions using the correlation
model. The beam is moved dynamically with the target
in order to maintain alignment of each treatment beam
in real time. Phantom experiments have showed that the
total system error is 1.07 mm when XLTS is used for
tracking tumors [6-10].
Patient eligibility
Patient inclusion criteria were a single primary or recur-
ring pulmonary lesion, T1 or T2 stage with a tumor
diameter between 15 and 60 mm without lymph nodeer: Live imaging from the CyberKnife; Right image: System
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ber 1, 2008, to January 1, 2011. Initial staging included
CT-Scan (thoracic, abdominal, and pelvic) with 18 F-
fluorodeoxyglucose positron emission tomography
(FDG-PET). Histological proof was obtained using trans-
thoracic or bronchoscopic biopsy. If histological proof
could not be obtained, patients were treated when the
lesion was considered evolutive, i.e., increasing in size on
two consecutive CT-Scans with uptake of FDG on a sin-
gle PET. Any lung-infectious process, particularly tuber-
culosis, was searched and ruled out before treatment.
Patients had a Performance Status under 2. Patients with
a history of other neoplasm were excluded. Each case
was discussed during our thoracic oncology department
staff meeting by a radiation oncologist, a medical on-
cologist, a radiologist, and a thoracic surgeon. Lesions
were considered surgically removable in patients not
amenable to surgery. Main inoperability reasons
included pre-existing medical conditions such as
advanced chronic obstructive pulmonary disease (GOLD
3, predicted FEV1< 49%), cardiovascular disease (ejec-
tion fraction< 40%), or general anaesthesia contraindica-
tions such as obesity (BMI> 30 kg/m2) or an history of
anaphylactic shock to the anaesthesia. Previous contra
or ipsilateral lung surgery or radiation therapy was
allowed. Patients did not receive chemotherapy before,
during, or after treatment until any progression. Written
informed consent was obtained from each patient.
Certain tumor characteristics were required for XLTS
to be able to detect the tumor: the tumor had to be at
least 15 mm in diameter, inside the lung parenchyma,
and at least 15 mm from any major vascular structure or
ribs. The projection of the tumor on the spine could not
be at a 45° angle because of the CyberKnife’s X-Ray tube
angulation.
Treatment planning, dose calculation, and treatment
session
A thin-sliced CT-scan without contrast was recorded
with millimetric slices. The gross tumor volume (GTV)
and organs at risk (spinal cord, left and right lung, heart,
and esophagus) were contoured on CT-Scan with the
following window and level setting: -600/1600 HU. A
geometrical 3-mm margin was added to the GTV toTable 1 Patient characteristics
Sex
Median
Tumor Size (mm) 24
Age (years) 68
Adenocarcinoma Squamous
Histology 10 (20%) 6 (10%)create the planning target volume (PTV). Treatments
were planned on Accuray's MultiplanW software. The
dose was calculated using the Ray-Tracing algorithm.
Dose was prescribed on the 83% isodose line. Dose con-
straints were as follow: total lung volume (defined as
right and left lung excluding PTV) receiving 5 Gy <50%
(V5 <50%), and V10 <30%; for heart, V24 was <15 cm3
and maximal dose <30 Gy; for trachea and bronchi, V15
was <4 cm3 and V20 <1 cm3, with maximum accept-
able point doses at 30 Gy. Maximum dose to esophagus
was 25 Gy and V21 was <5 cm3.
Study endpoints
The XLTS has already been validated on phantom
experiments13-17, but its clinical validity has not been
reported yet. The primary objective of this study was to
evaluate the local control rate achievable with XLTS.
The secondary objective was to evaluate the toxicity.
Local control was calculated from the time of treatment
until tumor relapse within PTV. Patients without local
relapse were censored on the day of the last follow-up.
Local relapse was defined as a 20% increase of the max-
imum diameter of the tumor on CT-Scan compared to
initial staging. Overall survival was calculated from the
start of radiotherapy until death from any cause.
Disease-specific survival was measured from the start of
radiotherapy until death from lung cancer. Patients alive
at last follow-up were censored. Follow-ups included a
CT-Scan at 3, 6, 9, and 12 months after treatment and
every 6 months after that; and an FDG-PET every
6 months. Treatment response was evaluated according
to RECIST (Response Evaluation Criteria In Solid
Tumors) v1.1 [11]. Toxicity was evaluated according to
CTCAE (National Cancer Institute Common Termin-
ology Criteria for Adverse Events) v4.0.
Statistics
SPSS (SPSS Inc., Chicago, Illinois, USA) version 13 soft-
ware was used for statistical analyses. Kaplan-Meier
method with 95% confidence intervals was used to esti-
mate local, overall, and specific survival. Cox regression
analysis was used to find prognostic values of patient
and tumor characteristics on local control and survival
endpoints. Differences between groups were illustratedMen Women




Cell Carcinoma Undifferenciated Unknown
3 (5%) 16 (62%)
Table 2 Technical characteristics of the treatments
Median Minimum Maximum
GTV (cm3) 12 1.6 115
PTV (cm3) 25 4 142
Median Minimum Maximum
Total Dose (Gy) 60 45 60
Dose/Fraction (Gy) 20 15 20
Number of treatment sessions 3 3 4
Duration of the sessions (min) 63 27 134
Number of treatment beams 70 20 163
Bibault et al. Radiation Oncology 2012, 7:102 Page 4 of 7
http://www.ro-journal.com/content/7/1/102with Kaplan-Meier curves and the log-rank test. All tests
were two-sided. A significance level α= 0.05 was used.
Results
Patient characteristics
Fifty-one patients were treated for non-small-cell lung
cancer with XLTS between November 1, 2008, and Janu-
ary 1, 2011. None of the patients were eligible for sur-
gery. Forty-three (84%) patients were men and eight
(16%) were women. Median age was 69 years (range,
50–85 years). All patients were smokers who had quit at
time of treatment. Histology was known for 19 patients
(38%): 10 were squamous-cell carcinomas (20%), six
adenocarcinomas (12%), and three undifferenciated can-
cers (6%). Thirty-one patients had T1 tumors and 20
had T2. Median tumor size was 24 mm (range, 15–
60 mm). Eight patients were treated for a recurrence
after prior surgery (n = 5) or radiation therapy (n = 3). All
51 patients had FDG-PET before treatment. The treat-
ment obviated the necessity to implant fiducials along
with its common sequelae such as pneuthorax. Main
characteristics are presented in Table 1.
Technical characteristics of performed treatments
Median delivered dose was 60 Gy (range, 45–60 Gy).
Three fractions were performed for the treatment, but ifFigure 2 Local control rates of patients treated with the Xsight Lungthe tumor was considered too close to mediastinal struc-
tures, the dose/fraction was lowered to 15 Gy and four
fractions were performed. This occurred in the case of
three patients. Median GTV was 11 cm3 (range, 1.6–
115 cm3) and median PTV was 25 cm3 (range, 4–
142 cm3). Median number of beams used was 70 (range,
20–163 beams), and median treatment session duration
was 63 minutes (range, 27–134 minutes). The dose was
prescribed to the 84% isodose line. Treatment character-
istics are presented in Table 2.
Treatment response
Median follow-up was 15 months (range, 5–30 months).
Actuarial local control was 92% (95% CI = 84–99%) at
1 year and 86% (95% CI = 75–97%) at 2 years (Figure 2).
Five patients (10%) experienced local failure along with
distant metastases to bone (n = 3), liver (n = 1), brain
(n = 2), or controlateral lung (n = 2). One patient’s re-
sponse to the treatment could not be evaluated on the
first CT-Scan at three months because of radiation
pneumonitis surrounding the treated tumor. However,
evaluation at 12 months showed a complete resolution
of the pneumonitis and a partial response. One patient
relapsed with mediastinal lymph node metastases two
years after treatment.
Actuarial overall survival was 85.5% (95% CI = 74.5–
96%) at 1 year and 79.4% (95% CI = 64–94.8%) at 2 years.
Seven patients died during follow-up, five from cancer
progression and two due to intercurrent disease. Actuar-
ial disease-specific survival was 90.1% (95% CI = 71–
100%) at 1 year and 84% (95% CI = 69–98%) at 2 years.
Prognostic factors for overall survival and local control
Patients, tumor and treatment characteristics were tested
as prognostic factors for overall survival and local control.
With regard to overall survival, no significant difference
based on sex (p= 0.254), age (p= 0.512), availability of
histologic data (p= 0.190), total dose delivered (p= 0.705),Tracking System (n = 51).
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a maximum tumor diameter under 3 cm tended to have a
better overall survival (p= 0.052). GTV greater than
10 cm3 was significantly associated with poorer survival
(100% vs. 65.2% at 2 years, p = 0.029, Figure 3).
Regarding local control, no significant difference was
observed based on sex (p = 0.886), age (p = 0.26), avail-
ability of histologic data (p = 0.98), tumor size
(p = 0.224), GTV (p = 0.171) or total dose delivered
(p = 0.33). A significant difference was found between
patients treated with three fractions and patients treated
with more than three fractions: the local control rate at
2 years was 100% for patients treated with three frac-
tions and 70% for patients treated with more than three
fractions (p = 0.006, Figure 4).
Toxicity
No pneumothorax was observed as we did not need
fiducials for tumor tracking. Seven cases of grade 1 radi-
ation pneumonitis (14%) without any clinical impact and
one grade 2 (2%) radiation pneumonitis were observed
at 3 months. No steroids were required for any of these
patients. Three grade 1 (6%) radiation fibroses were
observed on CT-Scan performed 1 year after treatment.
No acute or late grade 3 or 4 toxicities were observed.
Discussion
Several studies concerning SBRT for early-stage lung
cancer have been published. After White et al. published
a dose-escalation study in 2003, series reporting about
patients treated with CyberKnife began to emerge. In
2006, Nuyttens et al. wrote about 20 patients treated for
22 lung tumors [12]. The chosen method of treatment
required the use of fiducials. The reseachers used 78
markers to track the tumors: 34 were implanted using
transthoracic punction, 23 were endovascular coils, andFigure 3 Overall survival of patients with GTV>10 cm3 (n = 23) and p
Tracking System (p= 0.029).21 were extrathoracic. This study reported no pneumo-
thorax. Local control rate was 100% at four months. In
2007, Collins et al. published a study about 25 patients
also treated using fiducials [13]. Seven of the 25 patients
presented with pneumothorax. Another study published
in 2008 by Castelli et al. about 30 patients showed four
cases of pneumothorax and one fiducial migration [14].
The study with the most patients was published in 2009
by van der Voort van Zyp et al. [15]: 70 surgery-
ineligible patients (39 with T1 tumors and 31 with T2
tumors) were treated with 45 Gy or 60 Gy in three frac-
tions. Local control rate was 96% for patients treated
with 60 Gy and 78% for patients treated with 45 Gy. A
total of 225 fiducials were used (143 endovascular coils,
72 implanted using bronchoscopy, and 10 implanted by
transthoracic punction). One to five fiducials were used
for each patient for tumor tracking. Fiducial implant-
ation induced two grade 3 toxicities (one pneumothorax
requiring chest drain and an arrhythmia after intravascu-
lar coil placement), one grade 2 toxicity (pneumothorax),
and six grade 1 (dyspnea n = 1, pneumothorax n = 2, and
self-limiting hemorrhage, n = 3). These toxicities are not
frequent but cannot be neglected.
Our study is the first, to our knowledge to report only
on patients who were treated with a fiducial-free method
for tumor tracking. We report a local control rate of
88% at 15 months, which is comparable to other studies,
which indicates the method could be used without losing
efficacy. However, treatment time of over 60 minutes
can potentially be associated with loss of tumor BED of
> 10–15%, which will impact tumor control signifi-
cantly15. Median treatment time for our patient was 63
minutes (range, 27–134 minutes). This may explain our
local failure rate. Therefore, the number of pencil beams
should be kept to a minimum to decrease the treatment
time in cyberknife treatments.atients with GTV< 10 cm3 (n= 28) treated with the Xsight Lung
Figure 4 Local control rates of patients treated with three fractions (n = 27) and patients treated with more than three fractions
(n = 24) with Xsight Lung Tracking System (p= 0.006).
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local control rate than patients treated in three fractions.
This could be explained by the lower BED resulting from
the increased number of sessions for the same total dose
(BED for 60 Gy/4fx = 150 Gy vs BED for 60 Gy/
3fx = 180 Gy). The number of treatment session should
therefore be kept to three.
Five patients (10%) with local control relapsed with
distant metastases to bone (n = 3), liver (n = 1), brain
(n = 2), or the controlateral lung (n = 2). One patient
relapsed with mediastinal lymph node metastases 2 years
after treatment. A major limitation of our study was the
small number of patients with known histology (38%).
This is often the case in SBRT studies for lung cancer.
Van der Voort van Zyp et al. have reported an absence
of confirmation of malignancy in 49% of the patients.
Most of the patients are treated with SBRT because they
are too fragile for surgery or even trans-thoracic biop-
sies. However, Swensen et al. have created a malignancy
prediction model that, combined with FDG-PET [16],
could be useful for that matter.
We report seven grade 1 (14%) and two grade 2 (14%)
radiation pneumonitis cases and no grade 3 or 4 incidents.
These rates are lower than those that have been reported
by others (3–10% grade 3 toxicity) [17-19]. No patient had
any post-treatment pain or rib fractures. This may be due
to our strict selection criteria for XLTS, which mandated
that the tumors be at least 15 mm away from the ribs. We
observed three cases of grade 1 lung fibrosis.
There is an important need for multicenter randomized
trials comparing surgery to SBRT. An international rando-
mized prospective trial (STARS, ClinicalTrials.gov ID:
NCT00840749) was initiated by Accuray in collaboration
with the MD Anderson Cancer Center (Texas, USA) in
December 2008 to compare surgery to SBRT for operable
patients with early-stage non-small-cell lung cancer
tumors under 4 cm in diameter without lymph node ordistant metastases. Possible surgeries include: lobectomy,
bilobectomy, or pneumonectomy. The primary endpoint
is overall survival. On the other hand, the European multi-
center randomized trial (ROSEL, ClinicalTrials.gov ID:
NCT00687986) comparing SBRT to surgery for operable
patients has recently been terminated due to poor
recruitment.
Conclusion
Lung SBRT with fiducial-free tumor tracking is both
feasible and effective. Local control rate is similar to
what so far has been reported in other studies that have
used markers for tumor tracking. Toxicity was lower as
there was no fiducial implantation, thereby preventing
cases of pneumothorax normally associated with this
procedure. However, precise patient selection according
to simple criteria was required for the Xsight Lung Sys-
tem to work. This system is an interesting treatment op-
tion for patients not amenable to surgery or too fragile
for transthoracic punction and fiducial implantation. A
standard 3 x 20-Gy fractionation regimen should be
used to achieve optimal local control.
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Summary
SBRT is a growing field in the management of early-stage lung cancer.
Several methods are available to achieve precision: respiratory gating, body
frame, or real-time tumor tracking. Real-time tumor tracking can be
performed with fiducials or with a new method that tracks the tumor itself.
We report the first clinical study using this fiducial-free treatment. With local
control rates of 92% and 86% at 1 and 2 years, respectively, the results of
this method seem comparable to other studies that use fiducials.
Bibault et al. Radiation Oncology 2012, 7:102 Page 7 of 7
http://www.ro-journal.com/content/7/1/102Author details
1Academic Radiation Therapy Department, Lille II-Nord de France University,
CyberKnife Nord-Ouest, Oscar Lambret Comprehensive Cancer Center, 3, rue
Frédéric Combemale, BP 307-59020, LILLE Cedex, France. 2General Oncology
Department, Oscar Lambret Comprehensive Cancer Center, 3, rue Frédéric
Combemale, BP 307-59020, LILLE Cedex, France.
Received: 29 March 2012 Accepted: 24 June 2012
Published: 24 June 2012
References
1. Whyte RI, Crownover R, Murphy MJ, et al: Stereotactic radiosurgery for lung
tumors: preliminary report of a phase I trial. Ann Thor Surg. 2003, 75:1097.
2. Geraghty PR, Kee ST, McFarlane G, et al: CT-guided Transthoracic Needle
Aspiration Biopsy of Pulmonary Nodules: Needle Size and Pneumothorax
Rate. Radiology. 2003, 229:475–481.
3. Saji H, Nakamura H, Tsuchida T, et al: The Incidence and the Risk of
Pneumothorax and Chest Tube Placement After Percutaneous
CT-Guided Lung Biopsy. Chest. 2002, 121:1521–1526.
4. Reichner CA, Collins BT, Gagnon GJ, et al: The placement of gold fiducials for
CyberKnife stereotactic radiosurgery using a modified transbronchial needle
aspiration technique. J Bronchol. 2005, 12:193.
5. Yeow KM, Su I, et al: Risk Factors of Pneumothorax and Bleeding. Chest
2004, 126:748.
6. Fu D, Kahn R, Wang B, et al: Fiducial-free Lung Tumor Tracking for
CyberKnife Radiosurgery. Int J Radiat Oncol Biol Phys. 2008, 72:S608–S609.
7. Fu D, Kuduvalli G: Enhancing skeletal features in digitally reconstructed radiographs,
Dans: Medical Imaging. San Diego, CA, USA: Image Processing.Vol 6144; 2006.
8. Sayeh S, Wang J, Main W, Kilby W, Maurer C: Respiratory Motion Tracking
for Robotic Radiosurgery. Dans: Treating Tumors that Move with
Respiration. Springer. Urschel, Harold C 2007, 15:15–29.
9. Schweikard A, Glosser G, Bodduluri M, Murphy MJ, Adler JR: Robotic motion
compensation for respiratory movement during radiosurgery. Comput
Aided Surg. 2000, 5:263–277.
10. Schweikard A, Shiomi H, Adler J: Respiration tracking in radiosurgery. Med
Phys. 2004, 31:2738.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate
the response to treatment in solid tumors. European Organization for
Research and Treatment of Cancer, National Cancer Institute of the
United States, National Cancer Institute of Canada. J. Natl. Cancer Inst.
2000, 92:205–216.
12. Nuyttens JJ, Prévost J-B, Praag J, et al: Lung tumor tracking during
stereotactic radiotherapy treatment with the CyberKnife: Marker
placement and early results. Acta Oncol. 2006, 45:961–965.
13. Collins B, Erickson K, Reichner C, et al: Radical stereotactic radiosurgery
with real-time tumor motion tracking in the treatment of small
peripheral lung tumors. Radiat Oncol. 2007, 2:39.
14. Castelli J, Thariat J, Benezery K, et al: Analyse de la toxicité précoce des
traitements par CyberknifeW des cancers pulmonaires et résultats
préliminaires. Cancer Radiother. 2008, 12:793–799.
15. van Zyp NC Van der Voort, Prévost JB, Hoogeman MS, et al: Stereotactic
radiotherapy with real-time tumor tracking for non-small cell lung
cancer: Clinical outcome. Radiother Oncol 2009, 91:296–300.
16. Herder GJ, Van Tinteren H, Colding RP, et al: Clinical prediction model to
characterize pulmonary nodules: Validation and added value of
18 F-fluorodeoxyglucose positron emission tomography. Chest. 2005,
128:2490–2496.
17. Aoki T, Nagata Y, Negoro Y, et al: Evaluation of Lung Injury after Three-
dimensional Conformal Stereotactic Radiation Therapy for Solitary Lung
Tumors: CT Appearance. Radiology. 2004, 230:101–108.
18. Mehta V: Radiation pneumonitis and pulmonary fibrosis in non–small-cell
lung cancer: Pulmonary function, prediction, and prevention. Int J Radiat
Oncol Biol Phys. 2005, 63:5–24.
19. Takeda T, Takeda A, Kunieda E, et al: Radiation injury after
hypofractionated stereotactic radiotherapy for peripheral small lung
tumors: serial changes on CT. Am J Roentgenol. 2004, 182:1123.
doi:10.1186/1748-717X-7-102
Cite this article as: Bibault et al.: Image-Guided Robotic Stereotactic
Radiation Therapy with Fiducial-Free Tumor Tracking for Lung Cancer.
Radiation Oncology 2012 7:102.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
